A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice

被引:23
作者
Buffa, Viviana [1 ]
Negri, Donatella R. M. [1 ]
Leone, Pasqualina [1 ]
Bona, Roberta [1 ]
Borghi, Martina [1 ]
Bacigalupo, Ilaria [1 ]
Carlei, Davide [1 ]
Sgadari, Cecilia [1 ]
Ensoli, Barbara [1 ]
Cara, Andrea [1 ]
机构
[1] Ist Super Sanita, Dept Drugs & Evaluat, Natl AIDS Ctr, I-00161 Rome, Italy
关键词
D O I
10.1099/vir.0.81706-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Genetic immunization using viral vectors provides an effective means to elicit antigen-specific cellular immune responses. Several viral vectors have proven efficacious in inducing immune responses after direct injection in vivo. Among them, recombinant, self-inactivating lentiviral vectors are very attractive delivery systems, as they are able to efficiently transduce into and express foreign genes in a wide variety of mammalian cells. A self-inactivating lentiviral vector was evaluated for the delivery of human immunodeficiency virus 1 (HIV-1) envelope sequences in mice in order to elicit specific immune responses. With this aim, BALB/c mice were immunized with a single injection of self-inactivating lentiviral vectors carrying either the full-length HIV-1(HXB2) Rev/Env (TY2-IIIBEnv) or the codon-optimized HIV-1(JR-FL) gp120 (TY2-JREnv) coding sequence. Both vectors were able to elicit specific cellular responses efficiently, as measured by gamma interferon ELISPOT and chromium-release assays, upon in vitro stimulation of splenocytes from BALB/c immunized mice. However, only the TY2-JREnv-immunized mice were able to elicit specific humoral responses, measured as anti-gp120 antibody production. These data provide the first evidence that a single, direct, in vivo administration of a lentiviral vector encoding a viral gene might represent a useful strategy for vaccine development.
引用
收藏
页码:1625 / 1634
页数:10
相关论文
共 87 条
[21]   Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy [J].
Firat, H ;
Zennou, V ;
Garcia-Pons, F ;
Ginhoux, F ;
Cochet, M ;
Danos, O ;
Lemonnier, FA ;
Langlade-Demoyen, P .
JOURNAL OF GENE MEDICINE, 2002, 4 (01) :38-45
[22]  
Franchini Genoveffa, 2004, Expert Rev Vaccines, V3, pS75, DOI 10.1586/14760584.3.4.S75
[23]   Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes:: In vitro expression and immune responses in DNA-vaccinated mice [J].
Gao, F ;
Li, YY ;
Decker, JM ;
Peyerl, FW ;
Bibollet-Ruche, F ;
Rodenburg, CM ;
Chen, YL ;
Shaw, DR ;
Allen, S ;
Musonda, R ;
Shaw, GM ;
Zajac, AJ ;
Letvin, N ;
Hahn, BH .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (09) :817-823
[24]   Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ [J].
Gómez, CE ;
Abaitua, F ;
Rodríguez, D ;
Esteban, M .
VIRUS RESEARCH, 2004, 105 (01) :11-22
[25]  
Goulder PJR, 1999, AIDS, V13, pS121
[26]  
Grignani F, 1998, CANCER RES, V58, P14
[27]   Codon usage limitation in the expression of HIV-1 envelope glycoprotein [J].
Haas, J ;
Park, EC ;
Seed, B .
CURRENT BIOLOGY, 1996, 6 (03) :315-324
[28]   LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 [J].
Hacein-Bey-Abina, S ;
Von Kalle, C ;
Schmidt, M ;
McCcormack, MP ;
Wulffraat, N ;
Leboulch, P ;
Lim, A ;
Osborne, CS ;
Pawliuk, R ;
Morillon, E ;
Sorensen, R ;
Forster, A ;
Fraser, P ;
Cohen, JI ;
de Saint Basile, G ;
Alexander, I ;
Wintergerst, U ;
Frebourg, T ;
Aurias, A ;
Stoppa-Lyonnet, D ;
Romana, S ;
Radford-Weiss, I ;
Gross, F ;
Valensi, F ;
Delabesse, E ;
Macintyre, E ;
Sigaux, F ;
Soulier, J ;
Leiva, LE ;
Wissler, M ;
Prinz, C ;
Rabbitts, TH ;
Le Deist, F ;
Fischer, A ;
Cavazzana-Calvo, M .
SCIENCE, 2003, 302 (5644) :415-419
[29]   Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity [J].
He, YK ;
Zhang, JY ;
Mi, ZB ;
Robbins, P ;
Falo, LD .
JOURNAL OF IMMUNOLOGY, 2005, 174 (06) :3808-3817
[30]  
Heeney Jonathan Luke, 2004, Expert Rev Vaccines, V3, pS53, DOI 10.1586/14760584.3.4.S53